Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Patent
1994-06-06
1998-09-08
Spector, Lorraine M.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
514 12, 530350, A61K 3817
Patent
active
058041893
ABSTRACT:
Methods are provided for the treatment of symptoms of sepsis and other conditions that are mediated by the action of CD14 myelomonocytic antigen ("CD14"). The embodiments herein include treatments for symptoms of sepsis that are triggered by lipopolysaccharide ("LPS"). A genetically engineered recombinant soluble CD14 ("rsCD14") and fragments thereof are also provided. Both rsCD14 and a fragment thereof have been isolated and purified. The rsCD14 or fragments thereof can be administered to mammals to prevent or treat symptoms that are associated with sepsis.
REFERENCES:
Malizevski, Wright, CD14 and Immune Response to Lipopolysaccharide, Science, 252:1321-1322(1991).
Goyert et al., The CD14 Monocyte Differentiation Antigen Maps to a Region Encoding Growth Factors and Receptors, Science 239:497-500 (1988).
Ferrero et al., Nucleotide sequence of the gene encoding the monocyte differentiation antigen, CD14, Nuc. Acids Res., 16:4173(1986).
Matsuura et al., Nucleotide and amino acid sequences of the mouse CD14 gene, Nucleic Acids Research, 17:2132 (1989).
Setoguchi et al., Mouse and human CD14 (myeloid cell-specific leucine-rich glycoprotein) primary structure deduced from cDNA clones, Biochim. Biophys. Acta, 1008:213-222 (1989).
Bazil et al., Biochemical characterization of a soluble form of the 53-kDa monocyte surface antigen, Eur. J. Immunol., 16:1583-1589 (1986).
Lauener et al., Interleukin 4 down-regulates the expression of CD14 in normal human monocytes, Eur. J. Immunol. 20:2375-2381 (1990).
Lauener et al., Engagement of the Monocyte Surface Antigen CD14 Induces Lymphocytes Function Associated Antigen-1/Intercellular Adhesion Molecule Dependant Homotypic Adhesion, J. Immunol., 145:1390-1394 (1990).
Lund-Johansen et al., Signal transduction in human monocytes and granulocytes through the PI-linked antigen CD14, FEBS Letters, 273:1-2-55-88(1990).
Ulevitch et al., A New Model of Macrophage Stimulation by Bacterial Lipopolysaccharide, The Journal of Trauma, 30:189-192 (1990).
Ziegler et al., Treatment of Gram-Negative Bacteremia and Septic Shock with HA-1A Human Monoclonal Antibody Against Endotoxin, The New England Journal of Medicine, 324:429-436 (1991).
Haziot et al., Recombinant Soluble CD14 Inhibits LPS-Induced Tumor Necrosis Factor Necrosis Factor-.alpha. Production by Cells in Whole Blood, Journal of Immunology, 152:5868-5876 (1994). Jun. 15, 1994.
Scheirle et al., Peptide Binding to Soluble HLA-DR4 Molecules Produced by Insect Cells, Journal of Immunology, 149:1994-1999(1992).
Fraser, The Baculovirus-Infected Insect Cell as a Eukaryotic Gene Expression System, Curr. Topics Microbiol. Immunol., 158:148-172 (1992).
M. Arditi et al., Infect. Immun. 61(8):3149-3156, 1993.
C. Schutt et al., Res. Immunol. 143(1):71-78, Jan. 1992.
Cooper Iver P.
Goyert Sanna M.
Spector Lorraine M.
LandOfFree
Treatment of lipopolysaccharide- or CD14-mediated conditions usi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of lipopolysaccharide- or CD14-mediated conditions usi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of lipopolysaccharide- or CD14-mediated conditions usi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1279609